<!DOCTYPE html>
<html class="client-nojs" lang="en" dir="ltr">
<head>
<meta charset="UTF-8"/>
<title>Axenfeld Rieger Syndrome - EyeWiki</title>
<script>document.documentElement.className="client-js";RLCONF={"wgBreakFrames":!1,"wgSeparatorTransformTable":["",""],"wgDigitTransformTable":["",""],"wgDefaultDateFormat":"mdy","wgMonthNames":["","January","February","March","April","May","June","July","August","September","October","November","December"],"wgRequestId":"ZAVe87ydbNjqe1d87p-UIQAAAAQ","wgCSPNonce":!1,"wgCanonicalNamespace":"","wgCanonicalSpecialPageName":!1,"wgNamespaceNumber":0,"wgPageName":"Axenfeld_Rieger_Syndrome","wgTitle":"Axenfeld Rieger Syndrome","wgCurRevisionId":89603,"wgRevisionId":89603,"wgArticleId":974,"wgIsArticle":!0,"wgIsRedirect":!1,"wgAction":"view","wgUserName":null,"wgUserGroups":["*"],"wgCategories":["Articles","Glaucoma","Pediatric Ophthalmology/Strabismus"],"wgPageContentLanguage":"en","wgPageContentModel":"wikitext","wgRelevantPageName":"Axenfeld_Rieger_Syndrome","wgRelevantArticleId":974,"wgIsProbablyEditable":!1,"wgRelevantPageIsProbablyEditable":!1,"wgRestrictionEdit":[],
"wgRestrictionMove":[],"sdgDownArrowImage":"/w/extensions/SemanticDrilldown/skins/down-arrow.png","sdgRightArrowImage":"/w/extensions/SemanticDrilldown/skins/right-arrow.png","wgCiteDrawerEnableDesktop":!1,"wgCiteDrawerEnableMobile":!0,"wgCiteDrawerTheme":"dark","wgPageFormsTargetName":null,"wgPageFormsAutocompleteValues":[],"wgPageFormsAutocompleteOnAllChars":!1,"wgPageFormsFieldProperties":[],"wgPageFormsCargoFields":[],"wgPageFormsDependentFields":[],"wgPageFormsCalendarValues":[],"wgPageFormsCalendarParams":[],"wgPageFormsCalendarHTML":null,"wgPageFormsGridValues":[],"wgPageFormsGridParams":[],"wgPageFormsContLangYes":null,"wgPageFormsContLangNo":null,"wgPageFormsContLangMonths":[],"wgPageFormsHeightForMinimizingInstances":800,"wgPageFormsShowOnSelect":[],"wgPageFormsScriptPath":"/w/extensions/PageForms","edgValues":[],"wgPageFormsEDSettings":null,"wgAmericanDates":!0,"wgVisualEditor":{"pageLanguageCode":"en","pageLanguageDir":"ltr","pageVariantFallbacks":"en"},
"srfFilteredConfig":null,"wgEditSubmitButtonLabelPublish":!1};RLSTATE={"site.styles":"ready","noscript":"ready","user.styles":"ready","user":"ready","user.options":"loading","ext.cite.styles":"ready","mediawiki.ui.button":"ready","skins.chameleon":"ready","zzz.ext.bootstrap.styles":"ready","mediawiki.toc.styles":"ready","ext.CookieWarning.styles":"ready","oojs-ui-core.styles":"ready","oojs-ui.styles.indicators":"ready","mediawiki.widgets.styles":"ready","oojs-ui-core.icons":"ready","ext.visualEditor.desktopArticleTarget.noscript":"ready","ext.srf.styles":"ready","ext.smw.style":"ready","ext.smw.tooltip.styles":"ready"};RLPAGEMODULES=["ext.smw.style","ext.smw.tooltips","ext.cite.ux-enhancements","smw.entityexaminer","site","mediawiki.page.startup","mediawiki.page.ready","mediawiki.toc","ext.citedrawer.main","ext.CookieWarning","ext.visualEditor.desktopArticleTarget.init","ext.visualEditor.targetLoader","ext.eyeWiki","ext.eyeWiki.slideshow","sentry.init","ext.bootstrap.scripts"];</script>
<script>(RLQ=window.RLQ||[]).push(function(){mw.loader.implement("user.options@1hzgi",function($,jQuery,require,module){/*@nomin*/mw.user.tokens.set({"patrolToken":"+\\","watchToken":"+\\","csrfToken":"+\\"});
});});</script>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.CookieWarning.styles%7Cext.cite.styles%7Cext.visualEditor.desktopArticleTarget.noscript%7Cmediawiki.toc.styles%7Cmediawiki.ui.button%7Cmediawiki.widgets.styles%7Coojs-ui-core.icons%2Cstyles%7Coojs-ui.styles.indicators%7Cskins.chameleon%7Czzz.ext.bootstrap.styles&amp;only=styles&amp;skin=chameleon"/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.smw.style%7Cext.smw.tooltip.styles&amp;only=styles&amp;skin=chameleon"/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.srf.styles&amp;only=styles&amp;skin=chameleon"/>
<script async="" src="/w/load.php?lang=en&amp;modules=startup&amp;only=scripts&amp;raw=1&amp;skin=chameleon"></script>
<style>#mw-indicator-mw-helplink {display:none;}</style>
<meta name="ResourceLoaderDynamicStyles" content=""/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=site.styles&amp;only=styles&amp;skin=chameleon"/>
<meta name="generator" content="MediaWiki 1.35.8"/>
<meta name="description" content="Axenfeld-Rieger syndrome (ARS) refers to an autosomal dominant genetic condition characterized by anterior segment dysgenesis and systemic abnormalities. In 1920, Axenfeld characterized the anomaly which bears his name when he described posterior embryotoxon and iris strands adherent to the anteriorly displaced&amp;#160;Schwalbe’s line&amp;#91;1&amp;#93; (Figure 1). Posterior embryotoxon is a clinical and histologic term referring to displacement of Schwalbe’s line anterior to the limbus in the cornea.&amp;#160; Rieger described patients with congenital iris abnormalities including iris hypoplasia, corectopia, and polycoria, now referred to as Rieger anomaly, in 1935&amp;#91;2&amp;#93; (Figure 2). Rieger anomaly, associated with systemic findings, such as dental, facial bone defects including maxillary hypoplasia, umbilical abnormalities, or pituitary involvement is known as Rieger syndrome.&amp;#91;3&amp;#93;&amp;#91;4&amp;#93; The combination of Axenfeld anomaly and Reiger syndrome is known collectively as Axenfeld-Rieger syndrome."/>
<meta name="date" content="2022-12-24"/>
<meta name="WT.seg_1" content="0"/>
<meta name="google-site-verification" content="mtQvMIGqpWB4oyYM5mux15MHU-3qWI0bWtyRa2b5rlk"/>
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/>
<link rel="alternate" type="application/rdf+xml" title="Axenfeld Rieger Syndrome" href="/w/index.php?title=Special:ExportRDF/Axenfeld_Rieger_Syndrome&amp;xmlmime=rdf"/>
<link rel="shortcut icon" href="/w/extensions/EyeWiki/favicons/favicon.ico"/>
<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="EyeWiki (en)"/>
<link rel="EditURI" type="application/rsd+xml" href="https://eyewiki.org/w/api.php?action=rsd"/>
<link rel="preconnect" href="https://fonts.gstatic.com">
<link href="https://fonts.googleapis.com/css2?family=Lato:ital,wght@0,400;0,700;1,400&display=swap" rel="stylesheet">
<!-- Favicons MEYE-108 -->
<link rel="apple-touch-icon" sizes="120x120" href="/w/extensions/EyeWiki/favicons/apple-touch-icon.png">
<link rel="icon" type="image/png" sizes="32x32" href="/w/extensions/EyeWiki/favicons/favicon-32x32.png">
<link rel="icon" type="image/png" sizes="16x16" href="/w/extensions/EyeWiki/favicons/favicon-16x16.png">
<link rel="manifest" href="/w/extensions/EyeWiki/favicons/site.webmanifest">
<link rel="mask-icon" href="/w/extensions/EyeWiki/favicons/safari-pinned-tab.svg" color="#603cba">
<link rel="shortcut icon" href="/w/extensions/EyeWiki/favicons/favicon.ico">
<meta name="msapplication-TileColor" content="#603cba">
<meta name="msapplication-config" content="/w/extensions/EyeWiki/favicons/browserconfig.xml">
<meta name="theme-color" content="#ffffff">
<script> window.interdeal = { "sitekey": "81c701489fb8bb4ab90ca1cb0931f9c5", "Position": "Left", "Menulang": "EN", "domains": { "js": "https://cdn.equalweb.com/", "acc": "https://access.equalweb.com/" }, "btnStyle": { "vPosition": [ "80%", null ], "scale": [ "0.8", "0.8" ], "color": { "main": "#1876c9" }, "icon": { "type": 1, "outline": false } } }; (function(doc, head, body){ var coreCall = doc.createElement('script'); coreCall.src = 'https://cdn.equalweb.com/core/4.3.8/accessibility.js'; coreCall.defer = true; coreCall.integrity = 'sha512-u6i35wNTfRZXp0KDwSb3TntaIKI2ItCt/H/KcYIsBeVbaVMerEQLBnU5/ztfBg9aSW1gg7AN4CqCu9a455jkUg=='; coreCall.crossOrigin = 'anonymous'; coreCall.setAttribute('data-cfasync', true ); body? body.appendChild(coreCall) : head.appendChild(coreCall); })(document, document.head, document.body); </script>
<!--[if lt IE 9]><script src="/w/resources/lib/html5shiv/html5shiv.js"></script><![endif]-->
</head>
<body class="mediawiki ltr sitedir-ltr mw-hide-empty-elt ns-0 ns-subject page-Axenfeld_Rieger_Syndrome rootpage-Axenfeld_Rieger_Syndrome layout-standard skin-chameleon action-view">
	<div class="flex-fill container">
		<div class="row">
			<div class="flex-grow-0 col-12 col-cmln-6 d-flex flex-column flex-md-row w-md-100 justify-content-start align-items-center col">
					<div class="float-left mr-3 mb-2"><a href="//aao.org"><img id="aao-logo" src="/w/extensions/EyeWiki/skins/chameleon/AAO_Logo.png"></a></div>
                		
				<!-- logo and main page link -->
				<div id="p-logo" class="p-logo" role="banner">
					<a href="/Main_Page" title="Visit the main page"><img src="/w/extensions/EyeWiki/skins/chameleon/EyeWiki_Logo.png" alt="EyeWiki"/></a>
				</div>
			</div>
			<div class="ml-auto col-12 col-cmln col">
				<div class="row">
					<div class="col">
						<!-- personal tools -->
						<div class="p-personal pull-right" id="p-personal" >
							<ul class="p-personal-tools" >
								<li id="pt-createaccount"><a href="/w/index.php?title=Special:CreateAccount&amp;returnto=Axenfeld+Rieger+Syndrome" title="You are encouraged to create an account and log in; however, it is not mandatory" class="pt-createaccount">Create account</a></li>
								<li id="pt-login"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Axenfeld+Rieger+Syndrome" title="You are encouraged to log in; however, it is not mandatory [o]" accesskey="o" class="pt-login">Log in</a></li>
							</ul>
						</div>

					</div>
				</div>
				<div class="row">
					<div class="col">
						<!-- search form -->
						<div  id="p-search" class="p-search pull-right" role="search"  >
							<form  id="searchform" class="mw-search" action="/w/index.php" >
								<input type="hidden" name="title" value=" Special:Search" />
								<div class="input-group">
									<input name="search" placeholder="Search EyeWiki" title="Search EyeWiki [f]" accesskey="f" id="searchInput" class="form-control"/>
									<div class="input-group-append">
										<button value="Go" id="searchGoButton" name="go" type="submit" class="search-btn searchGoButton" aria-label="Go to page" title="Go to a page with this exact name if it exists"></button>
									</div>
								</div>
							</form>
						</div>
					</div>
				</div>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- navigation bar -->
				<nav class="p-navbar collapsible mb-3 mt-2 p-1 mt-cmln-0" role="navigation" id="mw-navigation">
					<button type="button" class="navbar-toggler" data-toggle="collapse" data-target="#hbpzfbovym"></button>
					<div class="collapse navbar-collapse hbpzfbovym" id="hbpzfbovym">
						<div class="navbar-nav"><div class="nav-item"><a class="nav-link fas fa-home"  href="/Main_Page">Main Page</a></div><div class="nav-item"><a class="nav-link fas fa-book"  href="/Category:Articles">Articles</a></div><div class="nav-item"><a class="nav-link fas fa-play"  href="/Help:Getting_Started">Getting Started</a></div><div class="nav-item"><a class="nav-link fas fa-question"  href="/Help:Contents">Help</a></div><div class="nav-item"><a class="nav-link fas fa-backward"  href="/Special:RecentChanges">Recent changes</a></div><div class="nav-item"><a class="nav-link fas fa-door-open"  href="#">My Portal</a></div>
						</div>
					</div>
				</nav>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- Content navigation -->
				<div class="mb-3 pagetools p-contentnavigation" id="p-contentnavigation">
					<!-- namespaces -->
					<div id="p-namespaces" class="p-namespaces">
						<div class="tab-group">
							<div id="ca-nstab-main" class="selected"><a href="/Axenfeld_Rieger_Syndrome" title="View the content page [c]" accesskey="c" class="selected ca-nstab-main">Page</a></div>
							<div id="ca-talk" class="new"><a href="/w/index.php?title=Talk:Axenfeld_Rieger_Syndrome&amp;action=edit&amp;redlink=1" rel="discussion" title="Discussion about the content page (page does not exist) [t]" accesskey="t" class="new ca-talk">Discussion</a></div>
						</div>
					</div>
					<!-- views -->
					<div id="p-views" class="p-views">
						<div class="tab-group">
							<div id="ca-formedit"><a href="/w/index.php?title=Axenfeld_Rieger_Syndrome&amp;action=formedit" title="Edit this page with a form [&amp;]" accesskey="&amp;" class="ca-formedit">View form</a></div>
							<div id="ca-viewsource"><a href="/w/index.php?title=Axenfeld_Rieger_Syndrome&amp;action=edit" title="This page is protected.&#10;You can view its source [e]" accesskey="e" class="ca-viewsource">View source</a></div>
							<div id="ca-history"><a href="/w/index.php?title=Axenfeld_Rieger_Syndrome&amp;action=history" title="Past revisions of this page [h]" accesskey="h" class="ca-history">History</a></div>
						</div>
					</div>
				</div>
			</div>
		</div>
		<div class="row">
			<div class="col-auto mx-auto col">

			</div>
		</div>
		<div class="row">
			<div class="col-auto mx-auto col">
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- start the content area -->
				<div id="content" class="mw-body content"><a id="top" class="top"></a>
					<div id="mw-indicators" class="mw-indicators">
					<div id="mw-indicator-smw-entity-examiner" class="mw-indicator mw-indicator-smw-entity-examiner"><div class="smw-entity-examiner smw-indicator-vertical-bar-loader" data-subject="Axenfeld_Rieger_Syndrome#0##" data-dir="ltr" data-uselang="" title="Running an examiner in the background"></div></div>
				</div>
						<div class="contentHeader">
						<!-- title of the page -->
						<h1 id="firstHeading" class="firstHeading">Axenfeld Rieger Syndrome</h1>
						<!-- tagline; usually goes something like "From WikiName" primary purpose of this seems to be for printing to identify the source of the content -->
						<div id="siteSub" class="siteSub">From EyeWiki</div><div id="jump-to-nav" class="mw-jump jump-to-nav">Jump to:<a href="#mw-navigation">navigation</a>, <a href="#p-search">search</a></div>
					</div>
					<div id="bodyContent" class="bodyContent">
						<!-- body text -->

						<div id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><div class="mw-parser-output"><div id="article-header" data-description2-ignore=""><div id="contest" style="margin-bottom: 6px;">
</div>
<div class="infobox contributors">
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header"><a href="/Property:Authors" title="Property:Authors">Article initiated by</a>:
</div>
<div class="info-section-body"><a href="/User:Schultzsk1" title="User:Schultzsk1">Scott K. Schultz, MD</a>
</div>
</div>
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">All authors and contributors:
</div>
<div class="info-section-body"> <a href="/User:Brad.H.Feldman.DEC" title="User:Brad.H.Feldman.DEC">Brad H. Feldman, M.D.</a>,&#160;<a href="/User:Schultzsk1" title="User:Schultzsk1">Scott K. Schultz, MD</a>,&#160;<a href="/User:Sarwat.Salim.SEC" title="User:Sarwat.Salim.SEC">Sarwat Salim MD, FACS</a>,&#160;<a href="/User:Ahmad.A.Aref" title="User:Ahmad.A.Aref">Ahmad A. Aref, MD, MBA</a>,&#160;<a href="/User:Chrysavgi.Adamopoulou" title="User:Chrysavgi.Adamopoulou">Chrysavgi Adamopoulou, MD</a>,&#160;<a href="/User:Koushik.Tripathy" title="User:Koushik.Tripathy">Koushik Tripathy, MD (AIIMS), FRCS (Glasgow)</a>,&#160;<a href="/User:John.Davis.Akkara" title="User:John.Davis.Akkara">Dr John Davis Akkara (MBBS, MS, FAEH, FMRF)</a>,&#160;<a href="/User:Kabir.Hossain" title="User:Kabir.Hossain">Dr. Kabir Hossain</a>,&#160;<a href="/User:Allison.R.Loh" title="User:Allison.R.Loh">Allison R. Loh, MD</a>,&#160;<a href="/User:Grace.Prakalapakorn" title="User:Grace.Prakalapakorn">S. Grace Prakalapakorn, MD, MPH</a>
</div>
</div>
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">Assigned editor:
</div>
<div class="info-section-body"> <a href="/User:Ahmad.A.Aref" title="User:Ahmad.A.Aref">Ahmad A. Aref, MD, MBA</a>,&#32;<a href="/User:Allison.Umfress" title="User:Allison.Umfress">Allison Umfress, MD</a></div>
</div><div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">Review:
</div>
<div class="info-section-body">Assigned status <b>Up to Date</b>
</div>
</div>&#160;by <a href="/User:Ahmad.A.Aref" title="User:Ahmad.A.Aref">Ahmad A. Aref, MD, MBA</a> on December 25, 2022.
</div>
<div style="display:none;">
<table cellspacing="5">

<tbody><tr>
<td><small><a rel="nofollow" class="external text" href="https://eyewiki.org/w/index.php?title=Axenfeld_Rieger_Syndrome&amp;action=formedit">add</a></small>
</td></tr>
<tr>
<th align="right"><b><a href="/Property:Contributing_Editors" title="Property:Contributing Editors">Contributing Editors</a>:</b>
</th>
<td><small><a rel="nofollow" class="external text" href="https://eyewiki.org/w/index.php?title=Axenfeld_Rieger_Syndrome&amp;action=formedit">add</a></small>
</td></tr>
</tbody></table> </div>
<div style="display:none;">
<p><br />
</p>
</div>
<div id="local-videos">
</div>
</div>
<div class="infobox vertical">
<div class="info-section vertical" style="margin-bottom: 10px;">
<div class="info-section-header">Axenfeld Rieger Syndrome
  </div>
<div class="info-section-body">
  </div>
</div>
<div class="info-section horizontal" style="margin-bottom: 10px;">
<div class="info-section-header"><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Diseases_Database">DiseasesDB</a>
        </div>
<div class="info-section-body"><a rel="nofollow" class="external text" href="http://www.diseasesdatabase.com/ddb30800.htm">30800</a>
        </div>
</div>
<div class="info-section horizontal" style="margin-bottom: 10px;">
<div class="info-section-header"><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/OMIM">OMIM</a>
        </div>
<div class="info-section-body"><a rel="nofollow" class="external text" href="http://omim.org/entry/180500">180500</a>
        </div>
</div>
<div class="info-section horizontal" style="margin-bottom: 10px;">
<div class="info-section-header"><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Medical_Subject_Headings">MeSH</a>
        </div>
<div class="info-section-body"><a rel="nofollow" class="external text" href="https://meshb.nlm.nih.gov/record/ui?ui=C535679">C535679</a>
        </div>
</div>
</div>
<p><br />
</p>
<div id="toc" class="toc" role="navigation" aria-labelledby="mw-toc-heading"><input type="checkbox" role="button" id="toctogglecheckbox" class="toctogglecheckbox" style="display:none" /><div class="toctitle" lang="en" dir="ltr"><h2 id="mw-toc-heading">Contents</h2><span class="toctogglespan"><label class="toctogglelabel" for="toctogglecheckbox"></label></span></div>
<ul>
<li class="toclevel-1 tocsection-1"><a href="#Introduction"><span class="tocnumber">1</span> <span class="toctext">Introduction</span></a></li>
<li class="toclevel-1 tocsection-2"><a href="#Genetics"><span class="tocnumber">2</span> <span class="toctext">Genetics</span></a></li>
<li class="toclevel-1 tocsection-3"><a href="#Epidemiology.2FPathophysiology"><span class="tocnumber">3</span> <span class="toctext">Epidemiology/Pathophysiology</span></a></li>
<li class="toclevel-1 tocsection-4"><a href="#Clinical_Characteristics"><span class="tocnumber">4</span> <span class="toctext">Clinical Characteristics</span></a></li>
<li class="toclevel-1 tocsection-5"><a href="#Glaucoma"><span class="tocnumber">5</span> <span class="toctext">Glaucoma</span></a>
<ul>
<li class="toclevel-2 tocsection-6"><a href="#Medical_Management"><span class="tocnumber">5.1</span> <span class="toctext">Medical Management</span></a></li>
<li class="toclevel-2 tocsection-7"><a href="#Surgical_Management"><span class="tocnumber">5.2</span> <span class="toctext">Surgical Management</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-8"><a href="#Other_Considerations"><span class="tocnumber">6</span> <span class="toctext">Other Considerations</span></a></li>
<li class="toclevel-1 tocsection-9"><a href="#Differential_Diagnosis"><span class="tocnumber">7</span> <span class="toctext">Differential Diagnosis</span></a>
<ul>
<li class="toclevel-2 tocsection-10"><a href="#ICE_.28Iridocorneal_Endothelial.29_Syndrome"><span class="tocnumber">7.1</span> <span class="toctext">ICE (Iridocorneal Endothelial) Syndrome</span></a></li>
<li class="toclevel-2 tocsection-11"><a href="#Peters.27_Anomaly"><span class="tocnumber">7.2</span> <span class="toctext">Peters' Anomaly</span></a></li>
<li class="toclevel-2 tocsection-12"><a href="#Aniridia_.28Iris_Hypoplasia.29"><span class="tocnumber">7.3</span> <span class="toctext">Aniridia (Iris Hypoplasia)</span></a></li>
<li class="toclevel-2 tocsection-13"><a href="#Congenital_Ectropion_Uveae"><span class="tocnumber">7.4</span> <span class="toctext">Congenital Ectropion Uveae</span></a></li>
<li class="toclevel-2 tocsection-14"><a href="#Ectopia_Lentis_et_Pupillae"><span class="tocnumber">7.5</span> <span class="toctext">Ectopia Lentis et Pupillae</span></a></li>
<li class="toclevel-2 tocsection-15"><a href="#Oculodentodigital_Dysplasia"><span class="tocnumber">7.6</span> <span class="toctext">Oculodentodigital Dysplasia</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-16"><a href="#Summary"><span class="tocnumber">8</span> <span class="toctext">Summary</span></a></li>
<li class="toclevel-1 tocsection-17"><a href="#Additional_Resources"><span class="tocnumber">9</span> <span class="toctext">Additional Resources</span></a></li>
<li class="toclevel-1 tocsection-18"><a href="#References"><span class="tocnumber">10</span> <span class="toctext">References</span></a></li>
</ul>
</div>

<h1><span class="mw-headline" id="Introduction">Introduction</span></h1>
<p>Axenfeld-Rieger syndrome (ARS) refers to an autosomal dominant genetic condition characterized by anterior segment dysgenesis and systemic abnormalities. In 1920, Axenfeld characterized the anomaly which bears his name when he described posterior embryotoxon and iris strands adherent to the anteriorly displaced&#160;Schwalbe’s line<sup id="cite_ref-axenfeld1_1-0" class="reference"><a href="#cite_note-axenfeld1-1">&#91;1&#93;</a></sup> (Figure 1). Posterior embryotoxon is a clinical and histologic term referring to displacement of Schwalbe’s line anterior to the limbus in the cornea.&#160; Rieger described patients with congenital iris abnormalities including iris hypoplasia, corectopia, and polycoria, now referred to as Rieger anomaly, in 1935<sup id="cite_ref-rieger2_2-0" class="reference"><a href="#cite_note-rieger2-2">&#91;2&#93;</a></sup> (Figure 2). Rieger anomaly, associated with systemic findings, such as dental, facial bone defects including maxillary hypoplasia, umbilical abnormalities, or pituitary involvement is known as Rieger syndrome.<sup id="cite_ref-shields3_3-0" class="reference"><a href="#cite_note-shields3-3">&#91;3&#93;</a></sup><sup id="cite_ref-shields4_4-0" class="reference"><a href="#cite_note-shields4-4">&#91;4&#93;</a></sup> The combination of Axenfeld anomaly and Reiger syndrome is known collectively as Axenfeld-Rieger syndrome. 
</p><p><a href="/File:Posterior_embryotoxon.JPG" class="image"><img alt="Posterior embryotoxon.JPG" src="/w/images/1/1/17/Posterior_embryotoxon.JPG" decoding="async" width="453" height="320" /></a>&#160;&#160;&#160;&#160; <a href="/File:Posterior_embryotoxon1.JPG" class="image"><img alt="Posterior embryotoxon1.JPG" src="/w/images/1/thumb/e/e7/Posterior_embryotoxon1.JPG/427px-Posterior_embryotoxon1.JPG" decoding="async" width="427" height="319" srcset="/w/images/1/e/e7/Posterior_embryotoxon1.JPG 1.5x" /></a>
</p><p>Figures 1, 2. Note in 1 and 2 the posterior embryotoxon, a white line anterior to the limbus in the cornea which is the abrnormal premature termination of Descemet’s membrane with the trabecular meshwork. In figure 2, note the corectopia and area of atrophy commonly seen in ARS (Images are Courtesy of Vanderbilt Eye Institute and Scott K. Schultz, MD.). 
</p>
<h1><span class="mw-headline" id="Genetics">Genetics</span></h1>
<p>Axenfled-Rieger syndrome is autosomal dominant in most cases, but it can also occur sporadically.<sup id="cite_ref-alward5_5-0" class="reference"><a href="#cite_note-alward5-5">&#91;5&#93;</a></sup> It has complete penetrance with variable expressivity and is associated with a 50% risk of glaucoma.<sup id="cite_ref-shields3_3-1" class="reference"><a href="#cite_note-shields3-3">&#91;3&#93;</a></sup><sup id="cite_ref-alward5_5-1" class="reference"><a href="#cite_note-alward5-5">&#91;5&#93;</a></sup><sup id="cite_ref-hjalt6_6-0" class="reference"><a href="#cite_note-hjalt6-6">&#91;6&#93;</a></sup> ARS is a genetically heterogeneous group of abnormalities as a result of mutations in at least 4 different gene loci. Mutations in PITX2 on chromosome 4q25, FOXC1 on 6p25, PAX6 on 11p13, and FOXO1A on 13q14 have been associated with formation of ARS.<sup id="cite_ref-glaser7_7-0" class="reference"><a href="#cite_note-glaser7-7">&#91;7&#93;</a></sup><sup id="cite_ref-semina8_8-0" class="reference"><a href="#cite_note-semina8-8">&#91;8&#93;</a></sup><sup id="cite_ref-nishimura9_9-0" class="reference"><a href="#cite_note-nishimura9-9">&#91;9&#93;</a></sup><sup id="cite_ref-phillips10_10-0" class="reference"><a href="#cite_note-phillips10-10">&#91;10&#93;</a></sup> FOXC1 and PITX2 both encode for transcription factors which regulate expression of downstream genetic targets by binding to specific DNA sequences and activating transcription. In mouse models, both FOXC1 and PITX2 are expressed in the ocular structures affected in ARS during embryogenesis.<sup id="cite_ref-berry11_11-0" class="reference"><a href="#cite_note-berry11-11">&#91;11&#93;</a></sup><sup id="cite_ref-smith12_12-0" class="reference"><a href="#cite_note-smith12-12">&#91;12&#93;</a></sup> Cases of ARS with mutations in CYP1B1 have also been reported.<sup id="cite_ref-13" class="reference"><a href="#cite_note-13">&#91;13&#93;</a></sup> 
</p>
<h1><span id="Epidemiology/Pathophysiology"></span><span class="mw-headline" id="Epidemiology.2FPathophysiology">Epidemiology/Pathophysiology</span></h1>
<p>This disorder is seen is approximately 1/200,000 live births.<sup id="cite_ref-14" class="reference"><a href="#cite_note-14">&#91;14&#93;</a></sup>&#160; There is no sex predilection.&#160; Most cases are diagnosed during infancy or childhood; however, glaucoma typically&#160;occurs in late childhood or adulthood.<sup id="cite_ref-shields3_3-2" class="reference"><a href="#cite_note-shields3-3">&#91;3&#93;</a></sup><sup id="cite_ref-shields4_4-1" class="reference"><a href="#cite_note-shields4-4">&#91;4&#93;</a></sup> 
</p><p>Defects in differentiation, migration, or arrested development of neural crest cells in the anterior chamber, facial bones, teeth, cardiovascular system, and periumbilical skin are considered to be the etiological basis for the systemic and ocular findings characteristic of ARS. 
</p><p>Histologically, patients with ARS have been found to have a monolayer of endothelial-like cells with a Descemet-like membrane extending from the cornea, across the anterior chamber and angle structures onto the surface of the iris. The membrane is typically found in the quadrant with associated the ectropion uveae/corectopia and the iris atrophy is found in the opposite quadrant.<sup id="cite_ref-shields4_4-2" class="reference"><a href="#cite_note-shields4-4">&#91;4&#93;</a></sup>  
</p><p>It is important to recognize that&#160;8-15% of the normal population may have a subtle, mild form of posterior embryotoxon without other sequelae, including glaucoma.<sup id="cite_ref-15" class="reference"><a href="#cite_note-15">&#91;15&#93;</a></sup> The posterior embryotoxon&#160;in ARS&#160;may be more dramatic and associated with other anterior segment findings, as described above.<sup id="cite_ref-burian13_16-0" class="reference"><a href="#cite_note-burian13-16">&#91;16&#93;</a></sup> 
</p>
<h1><span class="mw-headline" id="Clinical_Characteristics">Clinical Characteristics</span></h1>
<p>As mentioned, Axenfeld-Rieger syndrome is a bilateral, heterogeneous condition and may include developmental abnormalities in the anterior chamber angle, iris, and trabecular meshwork. Corectopia, polycoria, ectropion uveae, posterior embryotoxon, and increased intraocular pressure are common ophthalmologic findings with ARS. Photophobia may be a symptom resulting from the pupillary and iris abnormalities. 
</p><p>The most commonly recognized clinical manifestations of ARS are the iris corectopia/atrophy, and posterior embryotoxon (figures 1,2). Typically, the remainder of the cornea is clear. Occasional patients have megalocornea or microcornea. In some cases, the posterior embryotoxon may not be visible with the slit lamp examination. Shields published a case series of 24 patients with ARS, in which 5 patients had posterior embryotoxon visible only with gonioscopy.<sup id="cite_ref-shields3_3-3" class="reference"><a href="#cite_note-shields3-3">&#91;3&#93;</a></sup> 
</p><p>The iris strands adherent to the posterior embryotoxon can range from fine threadlike strands to broad bands of iris tissue. Likewise, the iris stroma may be grossly abnormal including generalized atrophy with corectopia, ectropion uveae, and often is similar in clinical appearance to iridocorneal endothelial syndrome (ICE).<sup id="cite_ref-shields4_4-3" class="reference"><a href="#cite_note-shields4-4">&#91;4&#93;</a></sup> Systemically, patients with ARS will commonly have mild craniofacial dysmorphism, dental abnormalities, and redundant umbilical skin. The facial abnormalities include hypertelorism, telecanthus, maxillary hypoplasia, and a broad, flat nasal bridge. Dental abnormalities include microdontia, oligodontia, or hypodontia. In addition, patients may have hypospadias, anal stenosis, pituitary abnormalities, growth retardation, and cardiac valvular abnormalities.<sup id="cite_ref-alward5_5-2" class="reference"><a href="#cite_note-alward5-5">&#91;5&#93;</a></sup><sup id="cite_ref-alkemade14_17-0" class="reference"><a href="#cite_note-alkemade14-17">&#91;17&#93;</a></sup><sup id="cite_ref-t.C3.BCmer15_18-0" class="reference"><a href="#cite_note-t.C3.BCmer15-18">&#91;18&#93;</a></sup><sup id="cite_ref-tsai16_19-0" class="reference"><a href="#cite_note-tsai16-19">&#91;19&#93;</a></sup><sup id="cite_ref-fitch17_20-0" class="reference"><a href="#cite_note-fitch17-20">&#91;20&#93;</a></sup> Abnormalities of the pituitary gland and other surrounding areas are less common, but more serious findings.  Cases of empty sella syndrome<sup id="cite_ref-21" class="reference"><a href="#cite_note-21">&#91;21&#93;</a></sup> and arachnoid cysts have been reported.<sup id="cite_ref-:0_22-0" class="reference"><a href="#cite_note-:0-22">&#91;22&#93;</a></sup> Growth hormone deficiency and short stature have also been described.<sup id="cite_ref-:0_22-1" class="reference"><a href="#cite_note-:0-22">&#91;22&#93;</a></sup>
</p>
<h1><span class="mw-headline" id="Glaucoma">Glaucoma</span></h1>
<p>Glaucoma is seen in approximately 50% of the cases with ARS. Development arrest of the neural crest cells with their retention in the anterior chamber angle during&#160;gestation results in incomplete development of the trabecular meshwork or Schlemm canal. The extent of iris defects and iris stands in the angle do not correlate well with the severity of glaucoma.&#160; However, the high iris insertion appears to be more pronounced in eyes with glaucoma.<sup id="cite_ref-shields3_3-4" class="reference"><a href="#cite_note-shields3-3">&#91;3&#93;</a></sup> Although glaucoma may present in early infancy, most cases occur during adolescence or early adulthood. 
</p>
<h2><span class="mw-headline" id="Medical_Management">Medical Management</span></h2>
<p>Medical management of congenital and childhood glaucoma is generally used as an adjunct to surgical interventions. Aqueous suppressants, including&#160;beta-blockers<sup id="cite_ref-boger18_23-0" class="reference"><a href="#cite_note-boger18-23">&#91;23&#93;</a></sup><sup id="cite_ref-hoskins19_24-0" class="reference"><a href="#cite_note-hoskins19-24">&#91;24&#93;</a></sup> and carbonic anhydrase inhibitors<sup id="cite_ref-portellos20_25-0" class="reference"><a href="#cite_note-portellos20-25">&#91;25&#93;</a></sup> have been shown to be safe and effective. These medications can&#160;have side-effects, especially in&#160;children with smaller volume of distribution for the&#160;drugs; therefore, these&#160;patients should be monitored closely. Prostaglandin analogues&#160;may be&#160;used to lower IOP (intraocular pressure).<sup id="cite_ref-enyedi21_26-0" class="reference"><a href="#cite_note-enyedi21-26">&#91;26&#93;</a></sup><sup id="cite_ref-black22_27-0" class="reference"><a href="#cite_note-black22-27">&#91;27&#93;</a></sup> Alpha-2 agonists, especially brimonidine, is contraindicated in children less than 2 years of age secondary to their association with potentially serious apnea, bradycardia, hypotension, hypotonia, and CNS (central nervous system) depression in this population.<sup id="cite_ref-carlsen23_28-0" class="reference"><a href="#cite_note-carlsen23-28">&#91;28&#93;</a></sup> Apraclonidine should be used with caution for the same considerations but seems to be safer than brimonidine.<sup id="cite_ref-wright24_29-0" class="reference"><a href="#cite_note-wright24-29">&#91;29&#93;</a></sup> For further discussion see: <a rel="nofollow" class="external text" href="https://eyewiki.aao.org/Congenital_Or_Infantile_Glaucoma#Management">Congenital_Or_Infantile_Glaucoma</a> 
</p>
<h2><span class="mw-headline" id="Surgical_Management">Surgical Management</span></h2>
<p>As in congenital glaucoma, surgical intervention is more efficacious than medical management in ARS.<sup id="cite_ref-beck25_30-0" class="reference"><a href="#cite_note-beck25-30">&#91;30&#93;</a></sup>However, achieving long term surgical success in congenital and developmental glaucoma is also difficult and complications are common.<sup id="cite_ref-bussi.C3.A8res26_31-0" class="reference"><a href="#cite_note-bussi.C3.A8res26-31">&#91;31&#93;</a></sup><sup id="cite_ref-beck29_32-0" class="reference"><a href="#cite_note-beck29-32">&#91;32&#93;</a></sup><sup id="cite_ref-sidoti30_33-0" class="reference"><a href="#cite_note-sidoti30-33">&#91;33&#93;</a></sup><sup id="cite_ref-coleman31_34-0" class="reference"><a href="#cite_note-coleman31-34">&#91;34&#93;</a></sup><sup id="cite_ref-eid32_35-0" class="reference"><a href="#cite_note-eid32-35">&#91;35&#93;</a></sup><sup id="cite_ref-englert33_36-0" class="reference"><a href="#cite_note-englert33-36">&#91;36&#93;</a></sup><sup id="cite_ref-djodeyre34_37-0" class="reference"><a href="#cite_note-djodeyre34-37">&#91;37&#93;</a></sup> Surgical options include, goniotomy, trabeculotomy, trabeculectomy with or without anitfibrotic agents, aqueous shunt procedures, or cyclodestructive procedures. In a retrospective review of pediatric glaucoma by Bussieres et al, 40% of patients with ARS had goniotomy, 30% had trabeculotomy, and 2% required glaucoma drainage devices.<sup id="cite_ref-bussi.C3.A8res26_31-1" class="reference"><a href="#cite_note-bussi.C3.A8res26-31">&#91;31&#93;</a></sup> Most of those patients required 1.5 surgeries per eye.<sup id="cite_ref-bussi.C3.A8res26_31-2" class="reference"><a href="#cite_note-bussi.C3.A8res26-31">&#91;31&#93;</a></sup>
</p><p>In general, goniotomy and trabeculotomy are less successful interventions in developmental glaucoma than other pediatric glaucomas, presumably because of the angle dysgenesis and other developmental abnormalities associated with this group of glaucomas.<sup id="cite_ref-luntz27_38-0" class="reference"><a href="#cite_note-luntz27-38">&#91;38&#93;</a></sup><sup id="cite_ref-taylor28_39-0" class="reference"><a href="#cite_note-taylor28-39">&#91;39&#93;</a></sup>
</p><p>Trabeculectomy with mitomycin C is associated with successful IOP lowering effect in 82-95% of cases and long-term success around 59% at 2-year follow-up.<sup id="cite_ref-beck29_32-1" class="reference"><a href="#cite_note-beck29-32">&#91;32&#93;</a></sup><sup id="cite_ref-sidoti30_33-1" class="reference"><a href="#cite_note-sidoti30-33">&#91;33&#93;</a></sup> However, this intervention is associated with&#160;risk of late post-operative endophthalmitis in 7-8% of cases.<sup id="cite_ref-sidoti30_33-2" class="reference"><a href="#cite_note-sidoti30-33">&#91;33&#93;</a></sup><sup id="cite_ref-coleman31_34-1" class="reference"><a href="#cite_note-coleman31-34">&#91;34&#93;</a></sup> 
</p><p>Glaucoma drainage devices have been reported to have&#160;success rates of 70-90% with long term success reported to be 58-63% at 2-year follow-up.<sup id="cite_ref-coleman31_34-2" class="reference"><a href="#cite_note-coleman31-34">&#91;34&#93;</a></sup><sup id="cite_ref-eid32_35-1" class="reference"><a href="#cite_note-eid32-35">&#91;35&#93;</a></sup><sup id="cite_ref-englert33_36-1" class="reference"><a href="#cite_note-englert33-36">&#91;36&#93;</a></sup><sup id="cite_ref-djodeyre34_37-1" class="reference"><a href="#cite_note-djodeyre34-37">&#91;37&#93;</a></sup><sup id="cite_ref-chen35_40-0" class="reference"><a href="#cite_note-chen35-40">&#91;40&#93;</a></sup> The rate of endophthalmitis is low with this procedure, 2.9%,<sup id="cite_ref-djodeyre34_37-2" class="reference"><a href="#cite_note-djodeyre34-37">&#91;37&#93;</a></sup> but surgical revision may have to be performed for other associated complications such as dislocation, tube-cornea touch, or erosion.<sup id="cite_ref-coleman31_34-3" class="reference"><a href="#cite_note-coleman31-34">&#91;34&#93;</a></sup><sup id="cite_ref-eid32_35-2" class="reference"><a href="#cite_note-eid32-35">&#91;35&#93;</a></sup><sup id="cite_ref-englert33_36-2" class="reference"><a href="#cite_note-englert33-36">&#91;36&#93;</a></sup> In addition, concomitant medical therapy is often necessary to augment IOP control with glaucoma drainage devices, and re-operation may be necessary.<sup id="cite_ref-beck25_30-1" class="reference"><a href="#cite_note-beck25-30">&#91;30&#93;</a></sup><sup id="cite_ref-eid32_35-3" class="reference"><a href="#cite_note-eid32-35">&#91;35&#93;</a></sup><sup id="cite_ref-englert33_36-3" class="reference"><a href="#cite_note-englert33-36">&#91;36&#93;</a></sup> In surgically refractory pediatric glaucomas, specifically developmental glaucomas,&#160;glaucoma drainage devices&#160;are likely to be successful where trabeculectomy has a relatively poor chance of success.<sup id="cite_ref-beck29_32-2" class="reference"><a href="#cite_note-beck29-32">&#91;32&#93;</a></sup><sup id="cite_ref-englert33_36-4" class="reference"><a href="#cite_note-englert33-36">&#91;36&#93;</a></sup> Cyclodestructive procedures are usually reserved for refractory glaucomas after other options have been exhausted because of low reported success rates, frequent need for re-treatment, and high complication rates.<sup id="cite_ref-beck25_30-2" class="reference"><a href="#cite_note-beck25-30">&#91;30&#93;</a></sup>
</p>
<h1><span class="mw-headline" id="Other_Considerations">Other Considerations</span></h1>
<p>As patients with ARS age, they may experience significant and debilitating glare or photophobia resulting from the sometimes progressive iris atrophy, polycoria, and corectopia. In these circumstances painted or tinted contact lenses may be beneficial in reducing these symptoms. 
</p>
<h1><span class="mw-headline" id="Differential_Diagnosis">Differential Diagnosis</span></h1>
<h2><span id="ICE_(Iridocorneal_Endothelial)_Syndrome"></span><span class="mw-headline" id="ICE_.28Iridocorneal_Endothelial.29_Syndrome">ICE (<a href="/Iridocorneal_Endothelial_Syndrome_and_Secondary_Glaucoma" title="Iridocorneal Endothelial Syndrome and Secondary Glaucoma">Iridocorneal Endothelial</a>) Syndrome</span></h2>
<p>Spectrum of disorders characterized by varying degrees of corneal edema, glaucoma, and iris abnormalities. Encompassed by three variations (1) Chandler’s Syndrome, (2) essential iris atrophy, (3) Cogan-Reese (iris nevus). ICE is typically unilateral, has female predominance, and manifests in early adulthood. Pathologically, it appears to be an acquired&#160;disease where endothelial cells acquire features of epithelial cells.&#160; Chandler’s syndrome is produced when the pathologic changes are confined to the inner corneal surface with dysfunction of the endothelial pump resulting in corneal edema. Essential iris atrophy is produced when the abnormal endothelium proliferates onto the iris surface with subsequent contractile membranes resulting in pupil corectopia, iris atrophy, polycoria. If the malformed and dysfunctional endothelium spreads across the anterior chamber angle, peripheral anterior synechiae develop and result in glaucoma. Cogan-Reese (iris nevus) is manifested by multiple pigmented iris nodules caused by contraction of the endothelial membranes on the surface of the iris.&#160; The unilateral nature, corneal endothelial changes, manifestation in middle age, female predominance, and lack of systemic abnormalities differentiate ICE from ARS.<sup id="cite_ref-shields4_4-4" class="reference"><a href="#cite_note-shields4-4">&#91;4&#93;</a></sup><sup id="cite_ref-external36_41-0" class="reference"><a href="#cite_note-external36-41">&#91;41&#93;</a></sup>
</p>
<h2><span id="Peters'_Anomaly"></span><span class="mw-headline" id="Peters.27_Anomaly"><a href="/Peters%27_Anomaly" class="mw-redirect" title="Peters&#39; Anomaly">Peters' Anomaly</a></span></h2>
<p>Characterized by a central corneal opacity associated with an absence of Descemet’s membrane and endothelial layers as well as variable degrees of iridocorneal adhesions from the border of the corneal opacity. <sup id="cite_ref-42" class="reference"><a href="#cite_note-42">&#91;42&#93;</a></sup> Around 60% of cases are bilateral and can be associated with congenital glaucoma, aniridia, and microcornea. Peters' can also be associated with systemic abnormalities including developmental delay, heart defects, hearing loss, CNS defects, gastrointestinal and genitourinary defects.
</p><p>Peters' anomaly is usually sporadic, but it can be inherited in an autosomal dominant or recessive pattern caused by PAX6, PITX2, CYP1B1, or FOXC1 genes. Although there are many similarities, the significant corneal changes differentiate Peters' from ARS.<sup id="cite_ref-external37_43-0" class="reference"><a href="#cite_note-external37-43">&#91;43&#93;</a></sup> 
</p>
<h2><span id="Aniridia_(Iris_Hypoplasia)"></span><span class="mw-headline" id="Aniridia_.28Iris_Hypoplasia.29"><a href="/Aniridia" title="Aniridia">Aniridia</a> (Iris Hypoplasia)</span></h2>
<p>A bilateral condition with variable appearance of the iris from a rudimentary stump to mild iris atrophy.<sup id="cite_ref-44" class="reference"><a href="#cite_note-44">&#91;44&#93;</a></sup> Aniridia is also characterized by pannus extending onto the central cornea from stem-cell deficiency, cataract, foveal hypoplasia, decreased vision, or nystagmus. Inheritance of aniridia is typically autosomal dominant, but 30% can be sporadic mutation in PAX6. 
</p><p>Aniridia is associated with a 50-75% risk of glaucoma, commonly resulting from rotation of the rudimentary iris into the anterior chamber angle obstructing aqueous outflow and may not occur until the second decade of life. One must consider WAGR (Wilms tumor, aniridia, genitourinary abnormalities, and mental retardation), an autosomal dominant form seen in 13% of patients with aniridia. Gillespie syndrome, an autosomal recessive form of aniridia, is associated with cerebellar ataxia and mental retardation seen in 2% of patients with aniridia. The conreal pannus, foveal hypoplasia, and iris hypoplasia differentiate aniridia from ARS.<sup id="cite_ref-glaucoma38_45-0" class="reference"><a href="#cite_note-glaucoma38-45">&#91;45&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="Congenital_Ectropion_Uveae">Congenital Ectropion Uveae</span></h2>
<p>Congenital displacement or dragging of the posterior pigmented epithelium of the pupil caused by contraction of myofibroblasts over the papillary margin.<sup id="cite_ref-46" class="reference"><a href="#cite_note-46">&#91;46&#93;</a></sup> Possibly a component of ARS, ICE, neurofibromatosis, facial hemihypertophy, Prader-Willi syndrome, but can be seen as an isolated finding. Congenital ectropion uveae can also be seen with rubeosis iridis. Unilateral congenital iris ectropion; smooth, cryptless iris surface; high iris insertion; dysgenesis of the anterior chamber angle; glaucoma is consistent with the diagnosis of congenital iris ectropion syndrome.<sup id="cite_ref-pediatric39_47-0" class="reference"><a href="#cite_note-pediatric39-47">&#91;47&#93;</a></sup><sup id="cite_ref-ophthalmic40_48-0" class="reference"><a href="#cite_note-ophthalmic40-48">&#91;48&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="Ectopia_Lentis_et_Pupillae">Ectopia Lentis et Pupillae</span></h2>
<p>A rare, bilateral, autosomal recessive condition characterized by displacement of the pupil, typically inferotemporally, associated with subluxation of the lens, usually in the opposite direction. This condition is also characterized by microsperophakia, miosis, and poor papillary dilation. Pathologically thought to be secondary to a defect in neuroectodermally derived tissues including the zonules, as well as the dilator muscle and pigmented layer of the pupil. Glaucoma is typically not a feature of ectopia lentis et pupillae.<sup id="cite_ref-pediatric41_49-0" class="reference"><a href="#cite_note-pediatric41-49">&#91;49&#93;</a></sup> 
</p>
<h2><span class="mw-headline" id="Oculodentodigital_Dysplasia">Oculodentodigital Dysplasia</span></h2>
<p>An autosomal dominant disorder characterized by pigmentary retinopathy, iris coloboma, congenital cataract, glaucoma, microcornea, microphthalmos, thin nose with narrow nostrils and hypoplastic alae, abnormality of the fourth and fifth fingers, and hypoplastic dental enamel. The lack of angle changes differentiates this entity from ARS.<sup id="cite_ref-retina42_50-0" class="reference"><a href="#cite_note-retina42-50">&#91;50&#93;</a></sup> 
</p>
<h1><span class="mw-headline" id="Summary">Summary</span></h1>
<p>Axenfled-Rieger syndrome is an autosomal dominant disorder with high penetrance, but variable expressivity associated with ocular as well as systemic developmental abnormalities secondary to genetic defects resulting from derangement in neural crest cell differentiation and migration. The most common ocular manifestations include a spectrum of posterior embryotoxon, iris atrophy, corectopia, and ectropion uveae with 50% of patients developing glaucoma. Systemic findings include mild craniofacial dysmorphism, dental and cardiovascular abnormalities, and redundant umbilical skin. Defects in PITX2, PAX6, FOXC1, and FOXO1A have been reported to cause ARS. Management primarily includes surgical management of the glaucoma, prevention of amblyopia, and possibly the use of painted contact lenses for associated photophobia. Life-long monitoring of these patients is important. 
</p>
<h1><span class="mw-headline" id="Additional_Resources">Additional Resources</span></h1>
<ul><li>Genetic and Rare Diseases Information Center (GARD). <a rel="nofollow" class="external text" href="https://rarediseases.info.nih.gov/diseases/5701/axenfeld-rieger-syndrome">Axenfeld-Rieger syndrome</a>. The Genetic and Rare Diseases (GARD) Information Center. <a rel="nofollow" class="external free" href="https://rarediseases.info.nih.gov/diseases/5701/axenfeld-rieger-syndrome">https://rarediseases.info.nih.gov/diseases/5701/axenfeld-rieger-syndrome</a> Accessed 29 March 2019.</li>
<li><a rel="nofollow" class="external text" href="http://health.groups.yahoo.com/group/RiegerSyndrome">Yahoo! groups: Reiger syndrome support groups</a></li>
<li><a rel="nofollow" class="external text" href="http://www.facebook.com/group.php?gid=6782676911">Facebook: Axenfled-Rieger Syndrome support group</a></li></ul>
<h1><span class="mw-headline" id="References">References</span></h1>
<div class="mw-references-wrap mw-references-columns"><ol class="references">
<li id="cite_note-axenfeld1-1"><span class="mw-cite-backlink"><a href="#cite_ref-axenfeld1_1-0">↑</a></span> <span class="reference-text">Axenfeld TH. Embryotoxon cornea posterius. Klin Monatsbl Augenheilkd. 1920;65:381-382.</span>
</li>
<li id="cite_note-rieger2-2"><span class="mw-cite-backlink"><a href="#cite_ref-rieger2_2-0">↑</a></span> <span class="reference-text">Rieger H. Beitrage zur Kenntnis seltener Missbildungen der Iris, II: uber Hypoplasie des Irisvorderblattes mit Verlagerung und entrundung der Pupille. Albrecht von Graefes Arch Klin Exp Ophthalmol. 1935;133:602-635.</span>
</li>
<li id="cite_note-shields3-3"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-shields3_3-0">3.0</a></sup> <sup><a href="#cite_ref-shields3_3-1">3.1</a></sup> <sup><a href="#cite_ref-shields3_3-2">3.2</a></sup> <sup><a href="#cite_ref-shields3_3-3">3.3</a></sup> <sup><a href="#cite_ref-shields3_3-4">3.4</a></sup></span> <span class="reference-text">Shields MB. Axenfeld-Rieger syndrome. A theory of mechanism and distinctions from the iridocorneal endothelial syndrome. Trans Am Ophthalmol Soc. 1983;81:736–84.</span>
</li>
<li id="cite_note-shields4-4"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-shields4_4-0">4.0</a></sup> <sup><a href="#cite_ref-shields4_4-1">4.1</a></sup> <sup><a href="#cite_ref-shields4_4-2">4.2</a></sup> <sup><a href="#cite_ref-shields4_4-3">4.3</a></sup> <sup><a href="#cite_ref-shields4_4-4">4.4</a></sup></span> <span class="reference-text">Shields MB. Axenfeld-Rieger and Iridocorneal Endothelial syndromes: Two spectra of Disease With Striking Similarities and Differences. J of Glaucoma. 2001;10(suppl 1):S36-S38.</span>
</li>
<li id="cite_note-alward5-5"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-alward5_5-0">5.0</a></sup> <sup><a href="#cite_ref-alward5_5-1">5.1</a></sup> <sup><a href="#cite_ref-alward5_5-2">5.2</a></sup></span> <span class="reference-text">Alward WLM: Axenfeld-Rieger syndrome in the age of molecular genetics. Am J Ophthalmol 2000;130:107-115.</span>
</li>
<li id="cite_note-hjalt6-6"><span class="mw-cite-backlink"><a href="#cite_ref-hjalt6_6-0">↑</a></span> <span class="reference-text">Hjalt TA, Semina EV: Current molecular understanding of Axenfeld-Rieger syndrome. Expert Rev Mol Med 2005;7:1-17.</span>
</li>
<li id="cite_note-glaser7-7"><span class="mw-cite-backlink"><a href="#cite_ref-glaser7_7-0">↑</a></span> <span class="reference-text">Glaser T, Walton DS, Maas RL. Genomic structure, evolutionary conservation and aniridia mutations in the human PAX6 gene. Nat Genet. 1992;2(3):232-239.</span>
</li>
<li id="cite_note-semina8-8"><span class="mw-cite-backlink"><a href="#cite_ref-semina8_8-0">↑</a></span> <span class="reference-text">Semina EV, Reiter R, Leysens NJ, et al. Cloning and characterization of a novel bicoid-related homeobox transcription factor gene, RIEG, involved in Rieger syndrome. Nat Genet. 1996; 14(4):392-399.</span>
</li>
<li id="cite_note-nishimura9-9"><span class="mw-cite-backlink"><a href="#cite_ref-nishimura9_9-0">↑</a></span> <span class="reference-text">Nishimura DY, Swiderski RE, Alward WL, et al. The forkhead transcription factor gene FKHL7 is responsible for glaucoma phenotypes which map to 6p25. Nat Genet. 1998; 19(2):140-147.</span>
</li>
<li id="cite_note-phillips10-10"><span class="mw-cite-backlink"><a href="#cite_ref-phillips10_10-0">↑</a></span> <span class="reference-text">Phillips JC, del Bono EA, Haines JL, et al. A second locus for Rieger syndrome maps to chromosome 13q14. Am J Hum Genet. 1996;59(3):613-619.</span>
</li>
<li id="cite_note-berry11-11"><span class="mw-cite-backlink"><a href="#cite_ref-berry11_11-0">↑</a></span> <span class="reference-text">Berry FB, Lines MA, Oas JM et al: Functional interactions between FOXC1 and PITX2 underlie the sensitivity to FOXC1 gene dose in Axenfeld –Rieger syndrome and anterior segment dysgenesis. Hum Mol Genet 2006;15: 905– 919.</span>
</li>
<li id="cite_note-smith12-12"><span class="mw-cite-backlink"><a href="#cite_ref-smith12_12-0">↑</a></span> <span class="reference-text">Smith RS, Zabaleta A, Kume T et al. Haploinsufficiency of the transcription factors FOXC1 and FOXC2 results in aberrant ocular development. Hum Mol Genet 2000;9:1021-1032.</span>
</li>
<li id="cite_note-13"><span class="mw-cite-backlink"><a href="#cite_ref-13">↑</a></span> <span class="reference-text">Tanwar M, Dada T, Dada R. Axenfeld-Rieger Syndrome Associated with Congenital Glaucoma and Cytochrome P4501B1 Gene Mutations. <i>Case Rep Med</i>. 2010;2010:212656. doi:10.1155/2010/212656</span>
</li>
<li id="cite_note-14"><span class="mw-cite-backlink"><a href="#cite_ref-14">↑</a></span> <span class="reference-text">Agarwal P, Jain K, Sandesh S, Chopra S. Axenfeld-Rieger Syndrome: Rare Case Presentation and Overview. <i>J Maxillofac Oral Surg</i>. 2020;19(3):364-369. doi:10.1007/s12663-019-01307-9</span>
</li>
<li id="cite_note-15"><span class="mw-cite-backlink"><a href="#cite_ref-15">↑</a></span> <span class="reference-text">Ho DK, Levin AV, Anninger WV, Piccoli DA, Eagle RC Jr. Anterior Chamber Pathology in Alagille Syndrome. <i>Ocul Oncol Pathol</i>. 2016;2(4):270-275. doi:10.1159/000446804</span>
</li>
<li id="cite_note-burian13-16"><span class="mw-cite-backlink"><a href="#cite_ref-burian13_16-0">↑</a></span> <span class="reference-text">Burian HM, Rice MH, Allen L. External visibility of the Schlemm’s canal. Arch Ophthalmol. 1957;57:651-658.</span>
</li>
<li id="cite_note-alkemade14-17"><span class="mw-cite-backlink"><a href="#cite_ref-alkemade14_17-0">↑</a></span> <span class="reference-text">Alkemade, P. Dysgenesis Mesodermalis of the Iris and the Cornea. Van Gorcum, Assen, The Netherlands. 1969. </span>
</li>
<li id="cite_note-t.C3.BCmer15-18"><span class="mw-cite-backlink"><a href="#cite_ref-t.C3.BCmer15_18-0">↑</a></span> <span class="reference-text">Tümer Z, Bach-Holm D. Axenfeld-Rieger syndrome and spectrum of PITX2 and FOXC1 mutations. Eur J Hum Genet. 2009 Dec;17(12):1527-39. Epub 2009 Jun 10.</span>
</li>
<li id="cite_note-tsai16-19"><span class="mw-cite-backlink"><a href="#cite_ref-tsai16_19-0">↑</a></span> <span class="reference-text">Tsai JC, Grajewski AL. Cardiac valvular disease and Axenfeld-Rieger syndrome. Am J Ophthalmol. 1994 Aug 15;118(2):255-6.</span>
</li>
<li id="cite_note-fitch17-20"><span class="mw-cite-backlink"><a href="#cite_ref-fitch17_20-0">↑</a></span> <span class="reference-text">Fitch N, Kaback M.The Axenfeld syndrome and the Rieger syndrome. J Med Genet. 1978 Feb;15(1):30-4.</span>
</li>
<li id="cite_note-21"><span class="mw-cite-backlink"><a href="#cite_ref-21">↑</a></span> <span class="reference-text">Shields MB, Buckley E, Klintworth GK, et al. Axenfeld–Rieger syndrome. A spectrum of developmental disorders. Surv Ophthalmol. 1985;29:387–409. doi: 10.1016/0039-6257(85)90205-X.</span>
</li>
<li id="cite_note-:0-22"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:0_22-0">22.0</a></sup> <sup><a href="#cite_ref-:0_22-1">22.1</a></sup></span> <span class="reference-text">Reis LM, Maheshwari M, Capasso J, et al. Axenfeld-Rieger syndrome: more than meets the eye [published online ahead of print, 2022 Jul 26]. <i>J Med Genet</i>. 2022;jmedgenet-2022-108646. doi:10.1136/jmg-2022-108646</span>
</li>
<li id="cite_note-boger18-23"><span class="mw-cite-backlink"><a href="#cite_ref-boger18_23-0">↑</a></span> <span class="reference-text">Boger WP, Walton DS: Timolol in uncontrolled childhood glaucoma. Ophthalmology. 1981;88:253–288.</span>
</li>
<li id="cite_note-hoskins19-24"><span class="mw-cite-backlink"><a href="#cite_ref-hoskins19_24-0">↑</a></span> <span class="reference-text">Hoskins HD, Hetherington J, Magee SD, et al: Clinical experience with timolol in childhood glaucoma. Arch Ophthalmol. 1985;103:1163–1165.</span>
</li>
<li id="cite_note-portellos20-25"><span class="mw-cite-backlink"><a href="#cite_ref-portellos20_25-0">↑</a></span> <span class="reference-text">Portellos M, Buckley EG, Freedman SF: Topical versus oral carbonic anhydrase inhibitor therapy for pediatric glaucoma. Journal of American Association of Pediatric Ophthalmology and Strabismus 1998;2:43–47.</span>
</li>
<li id="cite_note-enyedi21-26"><span class="mw-cite-backlink"><a href="#cite_ref-enyedi21_26-0">↑</a></span> <span class="reference-text">Enyedi LB, Freedman SF, Buckley EG: The effectiveness of latanoprost for the treatment of pediatric glaucoma. Journal of American Association of Pediatric Ophthalmology and Strabismus. 1999;3:33–39. </span>
</li>
<li id="cite_note-black22-27"><span class="mw-cite-backlink"><a href="#cite_ref-black22_27-0">↑</a></span> <span class="reference-text">Black AC, Jones S, Yanovitch TL, et al. Latanoprost in pediatric glaucoma--pediatric exposure over a decade. J AAPOS. 2009;13(6):558-62.</span>
</li>
<li id="cite_note-carlsen23-28"><span class="mw-cite-backlink"><a href="#cite_ref-carlsen23_28-0">↑</a></span> <span class="reference-text">Carlsen JO, Zabriskie NA, Kwon YH, et al: Apparent central nervous system depression in infants after the use of topical brimonidine. Am J Ophthalmol. 1999;128:255–256. </span>
</li>
<li id="cite_note-wright24-29"><span class="mw-cite-backlink"><a href="#cite_ref-wright24_29-0">↑</a></span> <span class="reference-text">Wright TM, Freedman SF. Exposure to topical apraclonidine in children with glaucoma. J Glaucoma. 2009;18(5):395-8.</span>
</li>
<li id="cite_note-beck25-30"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-beck25_30-0">30.0</a></sup> <sup><a href="#cite_ref-beck25_30-1">30.1</a></sup> <sup><a href="#cite_ref-beck25_30-2">30.2</a></sup></span> <span class="reference-text">Beck AD. Diagnosis and management of pediatric glaucoma. Ophthalmol Clin North Am. 2001;14(3):501-12.</span>
</li>
<li id="cite_note-bussi.C3.A8res26-31"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-bussi.C3.A8res26_31-0">31.0</a></sup> <sup><a href="#cite_ref-bussi.C3.A8res26_31-1">31.1</a></sup> <sup><a href="#cite_ref-bussi.C3.A8res26_31-2">31.2</a></sup></span> <span class="reference-text">Bussières JF, Therrien R, Hamel P, et al. Retrospective cohort study of 163 pediatric glaucoma patients. Can J Ophthalmol. 2009;44(3):323-7.</span>
</li>
<li id="cite_note-beck29-32"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-beck29_32-0">32.0</a></sup> <sup><a href="#cite_ref-beck29_32-1">32.1</a></sup> <sup><a href="#cite_ref-beck29_32-2">32.2</a></sup></span> <span class="reference-text">Beck AD, Wilson WR, Lynch MG, et al: Trabeculectomy with adjunctive mitomycin C in pediatric glaucoma. Am J Ophthalmol. 1998;126:648–657. </span>
</li>
<li id="cite_note-sidoti30-33"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-sidoti30_33-0">33.0</a></sup> <sup><a href="#cite_ref-sidoti30_33-1">33.1</a></sup> <sup><a href="#cite_ref-sidoti30_33-2">33.2</a></sup></span> <span class="reference-text">Sidoti, PA, Belmonte SJ, Liebmann JM, et al: Trabeculectomy with mitomycin–C in the treatment of pediatric glaucomas. Ophthalmology. 2000;107:422–429.</span>
</li>
<li id="cite_note-coleman31-34"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-coleman31_34-0">34.0</a></sup> <sup><a href="#cite_ref-coleman31_34-1">34.1</a></sup> <sup><a href="#cite_ref-coleman31_34-2">34.2</a></sup> <sup><a href="#cite_ref-coleman31_34-3">34.3</a></sup></span> <span class="reference-text">Coleman AL, Smyth RJ, Wilson MR, et al: Initial clinical experience with the Ahmed glaucoma valve implant in pediatric patients. Arch Ophthalmol. 1997;115:186–191.</span>
</li>
<li id="cite_note-eid32-35"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-eid32_35-0">35.0</a></sup> <sup><a href="#cite_ref-eid32_35-1">35.1</a></sup> <sup><a href="#cite_ref-eid32_35-2">35.2</a></sup> <sup><a href="#cite_ref-eid32_35-3">35.3</a></sup></span> <span class="reference-text">Eid TE, Katz LJ, Spaeth GL, et al: Long–term effects of tube–shunt procedures on management of refractory childhood glaucoma. Ophthalmology. 1997;104:1011–1016.</span>
</li>
<li id="cite_note-englert33-36"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-englert33_36-0">36.0</a></sup> <sup><a href="#cite_ref-englert33_36-1">36.1</a></sup> <sup><a href="#cite_ref-englert33_36-2">36.2</a></sup> <sup><a href="#cite_ref-englert33_36-3">36.3</a></sup> <sup><a href="#cite_ref-englert33_36-4">36.4</a></sup></span> <span class="reference-text">Englert JA, Freedman SF, Cox TA: The Ahmed valve in refractory pediatric glaucoma. Am J Ophthalmol. 1999;127:34–42.</span>
</li>
<li id="cite_note-djodeyre34-37"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-djodeyre34_37-0">37.0</a></sup> <sup><a href="#cite_ref-djodeyre34_37-1">37.1</a></sup> <sup><a href="#cite_ref-djodeyre34_37-2">37.2</a></sup></span> <span class="reference-text">Djodeyre MR, Peralta Calvo J, Abelairas Gomez J. Clinical evaluation and risk factors of time to failure of Ahmed Glaucoma Valve implant in pediatric patients. Ophthalmology. 2001;108(3):614-20.</span>
</li>
<li id="cite_note-luntz27-38"><span class="mw-cite-backlink"><a href="#cite_ref-luntz27_38-0">↑</a></span> <span class="reference-text">Luntz MH: Congenital, infantile, and juvenile glaucoma. Ophthalmology. 1979;86:793–802.</span>
</li>
<li id="cite_note-taylor28-39"><span class="mw-cite-backlink"><a href="#cite_ref-taylor28_39-0">↑</a></span> <span class="reference-text">Taylor RH, Ainsworth JR, Evans AR, et al: The epidemiology of pediatric glaucoma: The Toronto experience. Journal of American Association of Pediatric Ophthalmology and Strabismus. 1999;3:308–315.</span>
</li>
<li id="cite_note-chen35-40"><span class="mw-cite-backlink"><a href="#cite_ref-chen35_40-0">↑</a></span> <span class="reference-text">Chen TC, Bhatia LS, Walton DS. Ahmed valve surgery for refractory pediatric glaucoma: a report of 52 eyes. J Pediatr Ophthalmol Strabismus. 2005;42(5):274-83; quiz 304-5.</span>
</li>
<li id="cite_note-external36-41"><span class="mw-cite-backlink"><a href="#cite_ref-external36_41-0">↑</a></span> <span class="reference-text">External Disease and Cornea, Section 8. Basic and Clinical Science Course, AAO. Pg. 300-301;2009-2010.</span>
</li>
<li id="cite_note-42"><span class="mw-cite-backlink"><a href="#cite_ref-42">↑</a></span> <span class="reference-text">Jat NS, Tripathy K. Peters Anomaly. In: <i>StatPearls</i>. Treasure Island (FL): StatPearls Publishing; August 22, 2022.</span>
</li>
<li id="cite_note-external37-43"><span class="mw-cite-backlink"><a href="#cite_ref-external37_43-0">↑</a></span> <span class="reference-text">External Disease and Cornea, Section 8. Basic and Clinical Science Course, AAO. Pg. 292-294;2009-2010.</span>
</li>
<li id="cite_note-44"><span class="mw-cite-backlink"><a href="#cite_ref-44">↑</a></span> <span class="reference-text">Tripathy K, Salini B. Aniridia. In: <i>StatPearls</i>. Treasure Island (FL): StatPearls Publishing; August 22, 2022.</span>
</li>
<li id="cite_note-glaucoma38-45"><span class="mw-cite-backlink"><a href="#cite_ref-glaucoma38_45-0">↑</a></span> <span class="reference-text">Glaucoma, Section 10. Basic and Clinical Science Course, AAO. Pg. 162;2009-2010.</span>
</li>
<li id="cite_note-46"><span class="mw-cite-backlink"><a href="#cite_ref-46">↑</a></span> <span class="reference-text">Sridhar U, Tripathy K. Iris Ectropion Syndrome. In: <i>StatPearls</i>. Treasure Island (FL): StatPearls Publishing; August 22, 2022.</span>
</li>
<li id="cite_note-pediatric39-47"><span class="mw-cite-backlink"><a href="#cite_ref-pediatric39_47-0">↑</a></span> <span class="reference-text">Pediatric Ophthalmology and Strabismus, Section 6. Basic and Clinical Science Course, AAO. Pg. 169-170;2009-2010.</span>
</li>
<li id="cite_note-ophthalmic40-48"><span class="mw-cite-backlink"><a href="#cite_ref-ophthalmic40_48-0">↑</a></span> <span class="reference-text">Ophthalmic Pathology and Intraocular Tumors, Section 4. Basic and Clinical Science Course, AAO. Pg. 186;2009-2010.</span>
</li>
<li id="cite_note-pediatric41-49"><span class="mw-cite-backlink"><a href="#cite_ref-pediatric41_49-0">↑</a></span> <span class="reference-text">Pediatric Ophthalmology and Strabismus, Section 6. Basic and Clinical Science Course, AAO. Pg. 305-306;2009-2010.</span>
</li>
<li id="cite_note-retina42-50"><span class="mw-cite-backlink"><a href="#cite_ref-retina42_50-0">↑</a></span> <span class="reference-text">Retina and Vitreous, Section 12. Basic and Clinical Science Course, AAO. Pg. 256;2009-2010.</span>
</li>
</ol></div>
<!-- 
NewPP limit report
Cached time: 20230306033307
Cache expiry: 86400
Dynamic content: false
Complications: [my_variables_no_cache]
[SMW] In‐text annotation parser time: 0.002 seconds
CPU time usage: 0.297 seconds
Real time usage: 0.325 seconds
Preprocessor visited node count: 1555/1000000
Post‐expand include size: 14209/2097152 bytes
Template argument size: 2935/2097152 bytes
Highest expansion depth: 11/40
Expensive parser function count: 0/100
Unstrip recursion depth: 0/20
Unstrip post‐expand size: 25155/5000000 bytes
-->
<!--
Transclusion expansion time report (%,ms,calls,template)
100.00%  156.987      1 -total
 90.67%  142.344      1 Template:Article
 81.83%  128.470      8 Template:Infobox_section
 35.23%   55.314     16 Template:UserLookup
  9.27%   14.553      1 Template:Infobox_disease
  2.95%    4.629      1 Template:Review_expired
  0.88%    1.378      1 Template:Get_active_contest
  0.59%    0.921      2 Template:Infobox_begin
  0.57%    0.898      2 Template:Infobox_end
-->
</div></div><div class="printfooter">
Retrieved from "<a dir="ltr" href="https://eyewiki.org/w/index.php?title=Axenfeld_Rieger_Syndrome&amp;oldid=89603">https://eyewiki.org/w/index.php?title=Axenfeld_Rieger_Syndrome&amp;oldid=89603</a>"</div>

						<!-- end body text -->
						<!-- data blocks which should go somewhere after the body text, but not before the catlinks block-->
						<div id='mw-data-after-content'>
	<div class="mw-cookiewarning-container"><div class="mw-cookiewarning-text"><span>The Academy uses cookies to analyze performance and provide relevant personalized content to users of our website.</span></div><form method="POST"><div class='oo-ui-layout oo-ui-horizontalLayout'><span aria-disabled='false' class='oo-ui-widget oo-ui-widget-enabled oo-ui-buttonElement oo-ui-buttonElement-framed oo-ui-labelElement oo-ui-flaggedElement-progressive oo-ui-buttonWidget'><a role='button' tabindex='0' aria-disabled='false' href='https://www.aao.org/privacy-policy' rel='nofollow' class='oo-ui-buttonElement-button'><span class='oo-ui-iconElement-icon oo-ui-iconElement-noIcon oo-ui-image-progressive'></span><span class='oo-ui-labelElement-label'>Learn more</span><span class='oo-ui-indicatorElement-indicator oo-ui-indicatorElement-noIndicator oo-ui-image-progressive'></span></a></span><span aria-disabled='false' class='oo-ui-widget oo-ui-widget-enabled oo-ui-inputWidget oo-ui-buttonElement oo-ui-buttonElement-framed oo-ui-labelElement oo-ui-flaggedElement-primary oo-ui-flaggedElement-progressive oo-ui-buttonInputWidget'><button type='submit' tabindex='0' aria-disabled='false' name='disablecookiewarning' value='OK' class='oo-ui-inputWidget-input oo-ui-buttonElement-button'><span class='oo-ui-iconElement-icon oo-ui-iconElement-noIcon oo-ui-image-invert'></span><span class='oo-ui-labelElement-label'>Accept</span><span class='oo-ui-indicatorElement-indicator oo-ui-indicatorElement-noIndicator oo-ui-image-invert'></span></button></span></div></form></div>
</div>

					</div>
					<!-- category links -->
					<div id="catlinks" class="catlinks" data-mw="interface"><div id="mw-normal-catlinks" class="mw-normal-catlinks"><a href="/Special:Categories" title="Special:Categories">Categories</a>: <ul><li><a href="/Category:Articles" title="Category:Articles">Articles</a></li><li><a href="/Category:Glaucoma" title="Category:Glaucoma">Glaucoma</a></li><li><a href="/Category:Pediatric_Ophthalmology/Strabismus" title="Category:Pediatric Ophthalmology/Strabismus">Pediatric Ophthalmology/Strabismus</a></li></ul></div></div>
				</div>
			</div>
		</div>
	</div>
	<div class="mb-2 mt-4 footer container">
		<div class="row">
			<div class="col">
				<!-- navigation bar -->
				<nav class="p-navbar not-collapsible small mb-2" role="navigation" id="mw-navigation-hbpzfboxo3">
					<div class="navbar-nav">
					<!-- toolbox -->
					<div id="t-whatlinkshere" class="nav-item"><a href="/Special:WhatLinksHere/Axenfeld_Rieger_Syndrome" title="A list of all wiki pages that link here [j]" accesskey="j" class="nav-link t-whatlinkshere">What links here</a></div>
					<div id="t-recentchangeslinked" class="nav-item"><a href="/Special:RecentChangesLinked/Axenfeld_Rieger_Syndrome" rel="nofollow" title="Recent changes in pages linked from this page [k]" accesskey="k" class="nav-link t-recentchangeslinked">Related changes</a></div>
					<div id="t-specialpages" class="nav-item"><a href="/Special:SpecialPages" title="A list of all special pages [q]" accesskey="q" class="nav-link t-specialpages">Special pages</a></div>
					<div id="t-print" class="nav-item"><a href="javascript:print();" rel="alternate" title="Printable version of this page [p]" accesskey="p" class="nav-link t-print">Printable version</a></div>
					<div id="t-permalink" class="nav-item"><a href="/w/index.php?title=Axenfeld_Rieger_Syndrome&amp;oldid=89603" title="Permanent link to this revision of the page" class="nav-link t-permalink">Permanent link</a></div>
					<div id="t-info" class="nav-item"><a href="/w/index.php?title=Axenfeld_Rieger_Syndrome&amp;action=info" title="More information about this page" class="nav-link t-info">Page information</a></div>
					</div>
				</nav>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- footer links -->
				<div id="footer-info" class="footer-info">
					<!-- info -->
					<div> This page was last edited on February 13, 2023, at 04:55.</div>
					<div>This page has been accessed 294,170 times.</div>
				</div>
				<!-- places -->
				<div id="footer-places" class="footer-places">
					<div><a href="/EyeWiki:Privacy_policy" title="EyeWiki:Privacy policy">Privacy policy</a></div>
					<div><a href="/EyeWiki:About" title="EyeWiki:About">About EyeWiki</a></div>
					<div><a href="/EyeWiki:General_disclaimer" title="EyeWiki:General disclaimer">Disclaimers</a></div>
				</div>
			</div>
			<div class="col">
				<!-- footer icons -->
				<div id="footer-icons" class="justify-content-end footer-icons">
					<!-- poweredby -->
					<div><a href="https://www.mediawiki.org/"><img src="/w/resources/assets/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" srcset="/w/resources/assets/poweredby_mediawiki_132x47.png 1.5x, /w/resources/assets/poweredby_mediawiki_176x62.png 2x" width="88" height="31" loading="lazy"/></a></div>
					<div><a href="https://www.semantic-mediawiki.org/wiki/Semantic_MediaWiki"><img src="data:image/png;base64,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" alt="Powered by Semantic MediaWiki" class="smw-footer" width="88" height="31" loading="lazy"/></a></div>
				</div>
			</div>
		</div>
	</div>
<script src="https://www.googletagmanager.com/gtag/js?id=UA-64665049-1" async=""></script><script>
window.dataLayer = window.dataLayer || [];
function gtag(){dataLayer.push(arguments);}
gtag('js', new Date());
gtag('config', 'UA-64665049-1', {});
</script>

<script>(RLQ=window.RLQ||[]).push(function(){mw.config.set({"wgPageParseReport":{"smw":{"limitreport-intext-parsertime":0.002},"limitreport":{"cputime":"0.297","walltime":"0.325","ppvisitednodes":{"value":1555,"limit":1000000},"postexpandincludesize":{"value":14209,"limit":2097152},"templateargumentsize":{"value":2935,"limit":2097152},"expansiondepth":{"value":11,"limit":40},"expensivefunctioncount":{"value":0,"limit":100},"unstrip-depth":{"value":0,"limit":20},"unstrip-size":{"value":25155,"limit":5000000},"timingprofile":["100.00%  156.987      1 -total"," 90.67%  142.344      1 Template:Article"," 81.83%  128.470      8 Template:Infobox_section"," 35.23%   55.314     16 Template:UserLookup","  9.27%   14.553      1 Template:Infobox_disease","  2.95%    4.629      1 Template:Review_expired","  0.88%    1.378      1 Template:Get_active_contest","  0.59%    0.921      2 Template:Infobox_begin","  0.57%    0.898      2 Template:Infobox_end"]},"cachereport":{"timestamp":"20230306033307","ttl":86400,"transientcontent":false}}});mw.config.set({"wgBackendResponseTime":739});});</script></body>
</html>